Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines by Ornstein, David K., Gillespie, John W., Paweletz, Cloud P., Duray, Paul H., Herring, Judi, Vocke, Cathy D., Topalian, Suzanne L., Bostwick, David G., Linehan, W. Marston, Petricoin III, Emanuel F., Emmert-Buck, Michael R.

Get full text

Protein microarray platforms for clinical proteomics by Pollard, Harvey B., Srivastava, Meera, Eidelman, Ofer, Jozwik, Catherine, Rothwell, Stephen W., Mueller, Gregory P., Jacobowitz, David M., Darling, Thomas, Guggino, William B., Wright, Jerry, Zeitlin, Pamela L., Paweletz, Cloud P.

Get full text

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC by Recondo, Gonzalo, Bahcall, Magda, Spurr, Liam F, Che, Jianwei, Ricciuti, Biagio, Leonardi, Giulia C, Lo, Ying-Chun, Li, Yvonne Y, Lamberti, Giuseppe, Nguyen, Tom, Milan, Marina S D, Venkatraman, Deepti, Umeton, Renato, Paweletz, Cloud P, Albayrak, Adem, Cherniack, Andrew D, Price, Kristin S, Fairclough, Stephen R, Nishino, Mizuki, Sholl, Lynette M, Oxnard, Geoffrey R, Jänne, Pasi A, Awad, Mark M

Get full text

Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer by Liu, Joyce F., Doshi, Kshama A., Lee, Benjamin H., Peluso, Marisa O., Zhang, Li, Zhou, Shan, Zeng, Qing, Wang, Stephen, Kirschmeier, Paul T., Tran, Cam A., Paweletz, Cloud, Rausch, Matthew, Paterson, Alison M., Gokhale, Prafulla C., Matulonis, Ursula A.

Get full text

P1.01-46 Response Assessment Using Plasma Cell-Free DNA (cfDNA) – When Is the Optimal Time to Assess Response? by Cheng, M., Lau, C., Milan, M., Supplee, J., Riess, J., Bradbury, P., Paweletz, C., Oxnard, G.

Get full text

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer by Eser, Pınar Özden, Paranal, Raymond M, Son, Jieun, Ivanova, Elena, Kuang, Yanan, Haikala, Heidi M, To, Ciric, Okoro, Jeffrey J, Dholakia, Kshiti H, Choi, Jihyun, Eum, Yoonji, Ogino, Atsuko, Missios, Pavlos, Ercan, Dalia, Xu, Man, Poitras, Michael J, Wang, Stephen, Ngo, Kenneth, Dills, Michael, Yanagita, Masahiko, Lopez, Timothy, Lin, Mika, Tsai, Jeanelle, Floch, Nicolas, Chambers, Emily S, Heng, Jennifer, Anjum, Rana, Santucci, Alison D, Michael, Kesi, Schuller, Alwin G, Cross, Darren, Smith, Paul D, Oxnard, Geoffrey R, Barbie, David A, Sholl, Lynette M, Bahcall, Magda, Palakurthi, Sangeetha, Gokhale, Prafulla C, Paweletz, Cloud P, Daley, George Q, Jänne, Pasi A

Get full text

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors by Zhang, Weisheng, Haines, Brian B, Efferson, Clay, Zhu, Joe, Ware, Chris, Kunii, Kaiko, Tammam, Jennifer, Angagaw, Minilik, Hinton, Marlene C, Keilhack, Heike, Paweletz, Cloud P, Zhang, Theresa, Winter, Chris, Sathyanarayanan, Sriram, Cheng, Jonathan, Zawel, Leigh, Fawell, Stephen, Gilliland, Gary, Majumder, Pradip K

Get full text

Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer by Hanna, Glenn J., Lau, Christie J., Mahmood, Umair, Supplee, Julianna G., Mogili, Abhishek R., Haddad, Robert I., Jänne, Pasi A., Paweletz, Cloud P.

Get full text

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study by Schraa, S J, van Rooijen, K L, van der Kruijssen, D E W, Rubio Alarcón, C, Phallen, J, Sausen, M, Simmons, J, Coupé, V M H, van Grevenstein, W M U, Elias, S, Verkooijen, H M, Laclé, M M, Bosch, L J W, van den Broek, D, Meijer, G A, Velculescu, V E, Fijneman, R J A, Vink, G R, Koopman, M

Get full text